XENiOS
XENiOS AG specializes in developing medical devices aimed at treating acute and chronic lung failure, as well as cardiac insufficiency. The company offers a comprehensive range of products, including the iLA active platform for extrapulmonary lung support, iLA Membrane Ventilator for pumpless lung support, and various cannulas and pumps designed for cardiac surgery applications. Additionally, XENiOS provides innovative solutions such as the NovaTherm Heater/Cooler for blood temperature management and the deltastream series for monitoring and managing patient parameters during treatment. The company is uniquely positioned in the market by offering minimally invasive, disposable therapies that address both lung and heart conditions on a single platform, which is not available from other manufacturers. Founded in 2013 and based in Heilbronn, Germany, XENiOS AG also delivers clinical application support, training, and customer service to healthcare providers. As of late 2016, it operates as a subsidiary of Fresenius Medical Care AG & Co. KGaA.
Top Sectors
Top Regions
2 past transactions
Xor Labs Toronto
Venture Round in 2016
Xor Labs Toronto is a pioneering company in the field of personalized medicine for organ transplantation, focusing specifically on lungs. The company develops advanced medical devices aimed at supporting lung transplantation, particularly for patients suffering from critical conditions such as pulmonary fibrosis, cystic fibrosis, pulmonary hypertension, and chronic obstructive pulmonary disease. By enhancing the availability of donated lungs for transplantation, Xor Labs aims to significantly improve patient outcomes and reduce mortality rates associated with these diseases. Through its innovative approach, the company is transforming the landscape of organ transplantation on a global scale.
Xor Labs Toronto
Venture Round in 2016
Xor Labs Toronto is a pioneering company in the field of personalized medicine for organ transplantation, focusing specifically on lungs. The company develops advanced medical devices aimed at supporting lung transplantation, particularly for patients suffering from critical conditions such as pulmonary fibrosis, cystic fibrosis, pulmonary hypertension, and chronic obstructive pulmonary disease. By enhancing the availability of donated lungs for transplantation, Xor Labs aims to significantly improve patient outcomes and reduce mortality rates associated with these diseases. Through its innovative approach, the company is transforming the landscape of organ transplantation on a global scale.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.